Millennium Laboratories Announces Strategic Acquisition of RxAnte
News Jan 16, 2014
Millennium Laboratories has announced its acquisition of RxAnte, a health care predictive analytics and decision support company that improves population-level medication adherence on behalf of health plans, pharmacy benefit management companies, pharmacy chains, and health care providers. Terms of the transaction were not disclosed.
The acquisition will link two rapidly growing health care technology companies that share a strong commitment to improving the safe and effective use of prescription medications through personalized, technology-enabled drug therapy management solutions.
Millennium currently offers medication monitoring using urine drug testing (UDT) and pharmacogenetic testing (PGT) to health professionals treating, pain, substance use disorders, psychiatric disorders, and other chronic diseases. RxAnte is a venture-backed digital health care start-up launched in 2011 and based in the Washington, DC area. Investors in RxAnte included Aberdare Ventures and the West Health Investment Fund. Allen & Company LLC served as financial advisor to RxAnte in connection with this transaction.
RxAnte, whose predictive analytics and decision support platform now manages the medication adherence of over 8 million unique patients, will operate as a wholly owned subsidiary of Millennium. The company’s suite of products for payers and health care providers identifies patients at risk of avoidable costs due to improper medication use or non-adherence and then recommends specific steps for practitioners, pharmacists, and other members of the care team to support at-risk patients.
“Improving medication adherence is increasingly recognized as one of the biggest opportunities to improve patient outcomes and quality of care while slowing the growth of health care costs,” said Millennium’s CEO, Brock Hardaway. “The acquisition of RxAnte represents an exciting step for Millennium in continuing to pursue its strategic vision to improve care quality and health outcomes.”
RxAnte Founder and President, Josh Benner, said, “Payers and providers have strong, new incentives to help their patients get the most from their prescription medicines. What these organizations need now are the tools to help them target and tailor the right treatments and behavioral support to each patient. Together, RxAnte and Millennium offer a robust set of solutions for accomplishing exactly that.”
Beyond continuing to grow their respective core businesses, Millennium and RxAnte also plan to collaborate on new products and services to help payers and health care providers further personalize drug therapy management, improve population health, and reduce the avoidable costs of medication misuse.
Test For Designer Drugs Could Help Treat Overdose PatientsNews
Medical professionals are scrambling to meet the growing demand for emergency room treatment, but they’re hampered by the lack of a quick and easy test to screen patients for “designer” drugs. Chemists have now developed such a test and are refining it with the hope that hospitals could eventually use it to choose the appropriate treatment.READ MORE
Cancer ‘Signature’ First Step Toward Blood Test for PatientsNews
A discovery by Melbourne researchers could help to identify patients with a particularly aggressive type of lung cancer that are likely to respond to immunotherapies currently used in the clinic to treat other cancers.READ MORE
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018
World Congress on Plant Science and Molecular Biology
Sep 12 - Sep 13, 2018